Stockscreener 앱 받기
29.05
0.21%
-0.06
시간 외 거래:
29.05
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement - Bitget
Form 4 Stoke Therapeutics Inc For: 17 July By Investing.com - Investing.com Canada
Stoke Therapeutics (STOK) director gifts 303,190 options to trust - Stock Titan
Stoke Therapeutics (STOK) awards 225,000 stock options to Chief Scientific Officer - Stock Titan
Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report - Stock Titan
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group - MarketBeat
Stoke Therapeutics Inc (STOK) - MSN
Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44 - Moomoo
Stoke Tx appoints Thomas McCauley as CSO - The Pharma Letter
Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer - citybiz
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential - Investing.com UK
Stoke Therapeutics appoints Thomas McCauley as CSO By Investing.com - Investing.com Nigeria
Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer - Contract Pharma
Stoke Therapeutics Announces Appointment of Thomas McCauley as Chief Scientific Officer - marketscreener.com
Stoke Therapeutics appoints Thomas McCauley as CSO - Investing.com
Goldman Sachs Initiates Coverage on Stoke Therapeutics With Buy Rating, $44 Price Target - marketscreener.com
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer - Business Wire
STOK Initiates Coverage On Goldman Sachs -- Price Target Announced at $44 - GuruFocus
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential By Investing.com - Investing.com South Africa
Candriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat
(STOK) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT) - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Stoke Therapeutics Announces Updates to Timelines for the Complet - The National Law Review
Stoke Therapeutics highlights antisense pipeline as genetic medicine interest grows - ad-hoc-news.de
Stoke Therapeutics holds the focus. Investors await the next evidence - ad-hoc-news.de
Moran Wealth Management LLC Takes $1.32 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (STOK) CMO sells 7,228 shares in planned 10b5-1 trades - Stock Titan
Stoke Therapeutics faces earnings test after revenue miss By Investing.com - Investing.com Nigeria
Stoke Therapeutics (STOK) Receives a Buy from Jefferies - The Globe and Mail
STOK (NASDAQ) lists 7,228 RSUs and reports two 10b5-1 sales - Stock Titan
Stoke Therapeutics (STOK) Edges Lower as Stock Consolidates Near Key LevelsETF Flow - dars.gov.et
Responsive Playbooks and the STOK Inflection - Stock Traders Daily
Stoke completes phase 3 enrollment for Dravet syndrome drug - Investing.com UK
Stoke completes Phase 3 enrollment for Dravet drug study - grafa.com
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - BioSpace
Stoke Therapeutics Advances Zorevunersen in Dravet Syndrome Stud - GuruFocus
Stoke Therapeutics Completes Enrollment in Phase 3 Study of Zorevunersen for Dravet Syndrome Treatment - Moomoo
Stoke Therapeutics (STOK) Advances Phase 3 Study and NDA Plans - GuruFocus
Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial - TipRanks
Stoke completes phase 3 enrollment for Dravet syndrome drug By Investing.com - Investing.com Canada
Stoke CEO Ian Smith to speak April 14 at Needham healthcare event - Stock Titan
Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR; Q3 2027 readout, rolling NDA in 2027 - TradingView
Stoke Therapeutics (NASDAQ: STOK) completes Phase 3 Dravet trial enrollment, targets 2027 NDA - Stock Titan
Dravet Syndrome Foundation (DSF) Announces 2026 Community Award Winners - EIN Presswire
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell 3000E Index - marketscreener.com
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell Microcap Index - marketscreener.com
Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)? - simplywall.st
Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Assenagon Asset Management S.A. Sells 320,708 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
STOK Forecast — Price Target — Prediction for 2027 - TradingView
Stoke Therapeutics, Inc. Actuals & Estimates (NASDAQ:STOK) - TradingView
0GT Forecast — Price Target — Prediction for 2027 - TradingView
0.80%
2.11%
자본화:
|
볼륨(24시간):